Indeed, patients who received intramyocardial administration of autologous CD34+ cells (1 × 105 or 5 × 105) experienced a significant amelioration of angina frequency and exercise tolerance at 6 and 12 months from injection, and a reduction in mortality rate at 12 months (i.e., 5.4% in the placebo group vs no deaths in the treatment group) [111]. This evidence concerns the gene CD34 and angina pectoris.